Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

@article{Pepin2004ClostridiumDD,
  title={Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity},
  author={J. Pépin and L. Valiquette and M. Alary and Philippe Villemure and A. Pelletier and K. Forget and K. P{\'e}pin and Daniel Chouinard},
  journal={Canadian Medical Association Journal},
  year={2004},
  volume={171},
  pages={466 - 472}
}
Background: Recent reports suggest that Clostridium difficile colitis may be evolving into a more severe disease. During the second half of 2002 we noted an increase in the number of patients with severe C. difficile-associated diarrhea (CDAD) in our institution. We describe cases of CDAD at our institution over a 13-year period and investigate changes in illness severity. Methods: We undertook a retrospective chart review of all cases of CDAD diagnosed at the Centre hospitalier universitaire… Expand

Paper Mentions

Interventional Clinical Trial
The purpose of the study is to determine the safety and efficacy of Fecal Microbiota Transplant (FMT) for the treatment of the recurrence of Clostridium difficile infection (CDI… Expand
ConditionsClostridium Difficile Infection
InterventionBiological, Drug
Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.
  • J. Pépin, N. Saheb, +10 authors L. Lanthier
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile. Expand
Clinical Features of Clostridium difficile–Associated Infections and Molecular Characterization of Strains: Results of a Retrospective Study, 2000-2004
TLDR
The incidence of CDAD is low in this hospital, and cross-infection is limited, but results suggest that strains with binary toxin might be more virulent. Expand
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.
TLDR
A strain of C. difficile that was resistant to fluoroquinolones and had binary toxin and a partial deletion of the tcdC gene was responsible for this outbreak ofC.difficile-associated diarrhea. Expand
Epidemiology of Clostridium difficile-associated diarrhea in a Peruvian tertiary care hospital.
TLDR
Hospital transmission of C. difficile commonly occurred, supporting infection-appropriate measures directed toward the reduction of CDAD in low-resource settings. Expand
Update on Clostridium difficile associated disease
TLDR
The recent increase in the incidence and severity of Clostridium difficile associated disease may be related, at least in part, to the emergence of a highly virulent, fluoroquinolone-resistant, NAP1/027 strain. Expand
Changing Epidemiology of Clostridium difficile-Associated Disease in Children
TLDR
Findings from this study suggest that the characteristics of CDAD in children—a population that has not been considered to be at high risk for this disease in the past—are changing. Expand
Case fatality associated with a hypervirulent strain in patients with culture-positive Clostridium difficile infection: a retrospective population-based study.
TLDR
Infection due to a hypervirulent strain is a factor associated with increased case fatality in CDI and leukocyte count and CRP are useful prognostic biomarkers in patients with CDI. Expand
A Hospital-based Study of the Clinical Characteristics of Clostridium difficile Infection in Children
TLDR
A substantial proportion of pediatric CDI is CA and there are clinical differences between children with CA-CDI and HA- CDI, and early identification and treatment of CDI should be pursued in children with gastrostomy tube and recent hospitalization. Expand
Review: Clostridium difficile-Associated Disorders/Diarrhea and Clostridium difficile Colitis: The Emergence of a More Virulent Era
TLDR
The authors’ conclusions were that a previously uncommon strain of C. difficile with vari- with increased production of toxins A and B was found. Expand
Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease.
TLDR
A significant rise in Clostridium difficile-associated diarrhea was observed in both IBD and non-IBD patients, and the clinical outcome was favorable with only one IBD patient needing semi-urgent colectomy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.
  • R. Gaynes, D. Rimland, +4 authors F. Tenover
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2004
TLDR
It was concluded that an outbreak of CDAD in an LTCF was associated with a formulary change from levofloxacin to gatifloxAcin, and the rate ofCDAD in the LTCf decreased after a change back to levof loxacins. Expand
A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C. difficile Study Group.
TLDR
The age-specific incidence was little affected by gender but increased > 10-fold over the age range of 60-98 years, and the differences in overall CDAD incidence were sixfold between counties and threefold between major hospitals. Expand
Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991.
TLDR
CDAD usually responds to oral metronidazole or vancomycin but is nonetheless responsible for a high morbidity and occasional mortality in patients even when the diagnosis and treatment are pursued aggressively. Expand
Impact of changes in antibiotic policy on Clostridium difficile-associated diarrhoea (CDAD) over a five-year period in a district general hospital.
TLDR
It would appear that a short (typically three dose) course of third-generation cephalosporin poses a similar risk for CDAD as a more prolonged course, and the six-month delay in the decline of CDAD after virtual withdrawal of cep Halosporins may reflect a slowly diminishing environmental reservoir. Expand
Clostridium difficile colitis: an increasingly aggressive iatrogenic disease?
TLDR
Among patients with positive C difficile toxin assay results, immunocompromise and delayed diagnosis no longer seem to be associated with higher risk for death, and all patients taking antibiotics are at risk and require early recognition and aggressive medical intervention. Expand
Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study.
TLDR
This multicenter period prevalence study clearly supports the hypothesis of a common role of C difficile in infectious diarrhea in hospitalized patients. Expand
Clostridium difficile: clinical considerations.
TLDR
The historical data that led to the discovery of C. difficile, current information that is clinically relevant, and remaining issues of concern as a guide for future studies are reviewed. Expand
Epidemiology of community-acquired Clostridium difficile-associated diarrhea.
TLDR
Age-adjusted antibiotic-specific attack rates were at least 10-fold higher for nitrofurantoin, cefuroxime, cephalexin plus dicloxacillin, ampicillin/clavulanate plus cefaclor, and amicillin/ Clostridium difficile-associated diarrhea than forAmpicillin or amoxicillin; several other antibiotics were associated with similar but not significantly increased risks. Expand
Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications
TLDR
Key predictors of death after colectomy were preoperative vasopressor requirements and age, and surgical treatment of C. difficile colitis has a high death rate once the fulminant expression of the disease is present. Expand
Clostridium difficile-associated diarrhea in adults
TLDR
Treatment with oral vancomycin therapy should be reserved for patients who have contraindications or intolerance to metronidazole or who fail to respond to first-line therapy. Expand
...
1
2
3
4
...